Clinical and Applied Thrombosis/Hemostasis最新文献

{"title":"Validation of the RIETE, Kuijer, and HAS-BLED Models to Assess 3-Month Bleeding Risk in Anticoagulated Patients Diagnosed with Venous Thromboembolic Disease.","authors":"Stephanie Ortiz Gómez, Paula Ruiz-Talero, Oscar Muñoz, Luis Manuel Hoyos Pumarejo","doi":"10.1177/10760296241271351","DOIUrl":"10.1177/10760296241271351","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the discriminative ability and calibration of the RIETE, Kuijer, and HAS-BLED models for predicting 3-month bleeding risk in patients anticoagulated for venous thromboembolism (VTE).</p><p><strong>Methods: </strong>External validation study of a prediction model based on a retrospective cohort of patients with VTE seen at the Hospital Universitario San Ignacio, Bogotá (Colombia) between July 2021 and June 2023. The calibration of the scales was evaluated using the Hosmer-Lemeshow test and the ratio of observed to expected events (ROE) within each risk category. Discriminatory ability was assessed using the area under the curve (AUC) of a ROC curve.</p><p><strong>Results: </strong>We analyzed 470 patients (median age 65 years, female sex 59.3%) with a diagnosis of deep vein thrombosis in most cases (57.4%), 5.7% bleeding events were observed. Regarding calibration, adequate calibration cannot be ruled out given the limited number of events. The discriminatory ability was limited with an area under the curve (AUC) of 0.48 (CI 0.37-0.59) for Kuijer Score, 0.58 (CI 0.47-0.70) for HAS-BLED and 0.64 (CI 0.51-0.76) for RIETE.</p><p><strong>Conclusion: </strong>The Kuijer, HAS-BLED, and RIETE models in patients with VTE generally do not adequately estimate the risk of bleeding at three months, with a low ability to discriminate high-risk patients. Cautious interpretation is recommended until further evidence is available.</p>","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"30 ","pages":"10760296241271351"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141896945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a Predictive Model for Intracranial Haemorrhage in Patients on Direct Oral Anticoagulants.","authors":"Yuanyuan Liu, Linjie Li, Jingge Li, Hangkuan Liu, A Geru, Yulong Wang, Yongle Li, Ching-Hui Sia, Gregory Y H Lip, Qing Yang, Xin Zhou","doi":"10.1177/10760296241271338","DOIUrl":"10.1177/10760296241271338","url":null,"abstract":"<p><strong>Background: </strong>Intracranial haemorrhage (ICH) poses a significant threat to patients on Direct Oral Anticoagulants (DOACs), with existing risk scores inadequately predicting ICH risk in these patients. We aim to develop and validate a predictive model for ICH risk in DOAC-treated patients.</p><p><strong>Methods: </strong>24,794 patients treated with a DOAC were identified in a province-wide electronic medical and health data platform in Tianjin, China. The cohort was randomly split into a 4:1 ratio for model development and validation. We utilized forward stepwise selection, Least Absolute Shrinkage and Selection Operator (LASSO), and eXtreme Gradient Boosting (XGBoost) to select predictors. Model performance was compared using the area under the curve (AUC) and net reclassification index (NRI). The optimal model was stratified and compared with the DOAC model.</p><p><strong>Results: </strong>The median age is 68.0 years, and 50.4% of participants are male. The XGBoost model, incorporating six independent factors (history of hemorrhagic stroke, peripheral artery disease, venous thromboembolism, hypertension, age, low-density lipoprotein cholesterol levels), demonstrated superior performance in the development dateset. It showed moderate discrimination (AUC: 0.68, 95% CI: 0.64-0.73), outperforming existing DOAC scores (ΔAUC = 0.063, <i>P </i>= 0.003; NRI = 0.374, <i>P </i>< 0.001). Risk categories significantly stratified ICH risk (low risk: 0.26%, moderate risk: 0.74%, high risk: 5.51%). Finally, the model demonstrated consistent predictive performance in the internal validation.</p><p><strong>Conclusion: </strong>In a real-world Chinese population using DOAC therapy, this study presents a reliable predictive model for ICH risk. The XGBoost model, integrating six key risk factors, offers a valuable tool for individualized risk assessment in the context of oral anticoagulation therapy.</p>","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"30 ","pages":"10760296241271338"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11325470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis in Patients with ST-Segment Elevation Myocardial Infarction Reperfused by PHDP: 1-Year MACEs Follow-Up.","authors":"Jie Dou, Jie Gao, Hui-Hui Yang, Ruoling Guo, Chao Jiang, Jiang Zhou, Xiaomei Yu, Jingtao Guo, Jinlong Zhang, Donglei Luo","doi":"10.1177/10760296241271394","DOIUrl":"10.1177/10760296241271394","url":null,"abstract":"<p><p>This study explored 1-year follow-up of Parmaco-invasive strategy with half-dose recombinant human prourokinase (PHDP) in patients with acute ST-segment elevation myocardial infarction (STEMI). The follow-up endpoints were major adverse cardiovascular events (MACEs) occurring within 30 days and 1 year, as well as postoperative bleeding events. The study ultimately included 150 subjects, with 75 in the primary percutaneous coronary intervention (PPCI) group and 75 in the PHDP group. This study found that the PHDP group had a shorter FMC-reperfusion time (42.00 min vs 96.00 min, P < 0.001). During PCI, the PHDP group had a lower percutaneous transluminal coronary angioplasty (PTCA) (<i>P </i>= 0.021), intropin (<i>P </i>= 0.002) and tirofiban (<i>P </i>< 0.001) use. And the incidence of intraoperative arrhythmia, malignant arrhythmia, and slow flow/no-reflow was lower in the PHDP group (<i>P </i>< 0.001). At the 30-day follow-up, there was a significantly higher proportion of patients in the PPCI group who were readmitted due to unstable angina (<i>P </i>= 0.037). After 1 year of follow-up, there was no statistically significant difference in MACEs between the two groups (<i>P </i>= 0.500). The incidence of postoperative major bleeding, intracranial bleeding, and minor bleeding did not differ between the PHDP and PPCI groups (<i>P </i>> 0.05). The PHDP facilitates early treatment of infarct-related vessels, shortens FMC-reperfusion time, and does not increase the risk of MACEs.</p>","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"30 ","pages":"10760296241271394"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11325463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abnormal serum Magnesium Level is Associated with the Coagulopathy in Traumatic Brain Injury Patients.","authors":"Ruoran Wang, Jianguo Xu, Min He","doi":"10.1177/10760296241280919","DOIUrl":"10.1177/10760296241280919","url":null,"abstract":"<p><strong>Background: </strong>Coagulopathy is associated with poor prognosis of traumatic brain injury (TBI) patients. This study is performed to explore the association between serum magnesium level and the risk of coagulopathy in TBI.</p><p><strong>Methods: </strong>TBI patients from the Medical Information Mart for Intensive Care-III database were included for this study. Logistic regression analysis was performed to explore risk factors and develop a predictive model for coagulopathy in TBI. The restricted cubic spline (RCS) was utilized to analyze the association between serum magnesium level and the development of coagulopathy. Receiver operating characteristic curve was drawn to evaluate the performance of the predictive model for coagulopathy.</p><p><strong>Results: </strong>The incidence of coagulopathy in TBI was 32.6%. The RCS indicated the association between magnesium and coagulopathy was U-shaped. Multivariate logistic regression confirmed age, coronary heart disease, cerebral vascular disease, chronic liver disease, GCS, ISS, epidural hematoma, hemoglobin, shock index and magnesium level were independently associated with the coagulopathy in TBI. Compared with patients of magnesium level between 1.7 and 2.3 mg/dL, those with magnesium level below 1.7 mg/dL or above 2.2 mg/dL had a higher risk of coagulopathy.</p><p><strong>Conclusion: </strong>Both hypermagnesemia and hypomagnesemia are associated with higher risk of coagulopathy in TBI patients. Physicians should pay more attention on preventing coagulopathy in TBI patients with hypomagnesemia or hypermagnesemia.</p>","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"30 ","pages":"10760296241280919"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Fixed Versus Weight-Based Prothrombin Complex Concentrate Dosing Strategies for Factor Xa Inhibitor Reversal.","authors":"Snyder Brett, Miller Taylor, McCormick Pamela, Gionfriddo Michael","doi":"10.1177/10760296241243368","DOIUrl":"10.1177/10760296241243368","url":null,"abstract":"<p><p><b>Background:</b> Our institution introduced fixed-dose prothrombin complex concentrate (PCC) to streamline order verification and medication administration. Previous studies using fixed-dose PCC for vitamin K antagonist reversal showed comparable efficacy to weight-based dosing. <b>Objective:</b> To compare fixed versus weight-based PCC dosing for reversal of Factor Xa Inhibitor (FXaI) effects. <b>Methods:</b> Retrospective cohort study conducted at a tertiary care academic medical center. Patients who received PCC to reverse the effects of apixaban or rivaroxaban were eligible. Subjects in the fixed-dose group (5000 units or 2000 units) were compared to weight-based PCC (50 units/kg). The primary outcome was time between order entry and medication administration. Secondary outcomes included: average PCC dose, postadministration procedures, achieved hemostasis, 30-day mortality, hospital length of stay, and adverse drug events. <b>Results:</b> 72 patients received fixed-dose PCC and 101 received weight-based PCC. Median time between order entry and administration was 4.5 min shorter in the fixed-dose group compared to weight-based (34.5 vs 39 min, <i>P</i> = .10). In patients who received fixed-dose, 79.2% achieved hemostasis versus 71.3% in the weight-based group (RR = 1.11, 95% CI = 0.94-1.32). There was no difference in the number of subsequent hemorrhage-related surgeries (29.2% vs 36.7%, RR = 0.80, 95% CI = 0.51-1.24) or mortality rate (26.4% vs 35.6%, RR = 0.73, 95% CI = 0.46-1.17). There were zero adverse drug events reported. Rates of thrombosis were 2.8% and < 1% (<i>P</i> = .57) in the fixed and weight-based groups, respectively. <b>Conclusion and Relevance:</b> The fixed-dosing strategy did not reduce time to PCC administration nor impact hemostasis or mortality. These data support that the fixed-dosing method is a viable option.</p>","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"30 ","pages":"10760296241243368"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140857690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Rivaroxaban Versus Warfarin After inferior Vena cava Filter Implantation: A Retrospective Cohort Study.","authors":"Ilya Schastlivtsev, Aleksey Pankov, Sergey Tsaplin, Evgeny Stepanov, Sergey Zhuravlev, Kirill Lobastov","doi":"10.1177/10760296241256938","DOIUrl":"10.1177/10760296241256938","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the efficacy and safety of rivaroxaban compared to warfarin after inferior vena cava (IVC) filter implantation.</p><p><strong>Method: </strong>This retrospective analysis includes data from 100 patients with deep vein thrombosis (DVT) who underwent IVC filter implantation due to a free-floating thrombus (n = 64), thrombus propagation (n = 8), or acute bleeding (n = 8) on therapeutic anticoagulation, catheter-directed thrombolysis (n = 8), or had previously implanted filter with DVT recurrence. Patients were treated with warfarin (n = 41) or rivaroxaban (n = 59) for 3-12 months. Symptomatic venous thromboembolism (VTE) recurrence and bleeding events were assessed at 12 months follow-up.</p><p><strong>Results: </strong>Three (7.3%) cases of VTE recurrence without IVC filter occlusion occurred on warfarin and none on rivaroxaban. The only (2.4%) major bleeding occurred on warfarin. Three (5.1%) clinically relevant non-major bleedings were detected on rivaroxaban. No significant differences existed between groups when full and propensity scores matched datasets were compared.</p><p><strong>Conclusions: </strong>Rivaroxaban seems not less effective and safe than warfarin after IVC filter implantation.</p>","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"30 ","pages":"10760296241256938"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11113020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141080726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous Thromboembolism Risk and Adherence to Pharmacological Thromboprophylaxis in Hospitalized Patients in Uruguay: First Nationwide Study.","authors":"Valentina Mérola, Ana Carina Pizzarossa, Maynés López, Franco Peverelli, Gustavo Bruno, Mariana González, Federico Roca, Leticia Dentone, Gerardo Pérez, Lucía Da Silveira, Lilián Díaz, Josefina Tafuri, Rosario Cuadro, Martín Zaquiere, Guillermina Bartaburu, Franco Pacello, Carina Celio, María José López, Marcelo Viana, Laura Fraga, Valeria Blanco, Paula Chalart, Daniel Leal, Xilef Rodríguez, Laura Teti, Carolina Goñi, Eduardo Infante, Alejandra Prícoli, Victoria Altieri, Cecilia Guillermo, Rosario Martínez","doi":"10.1177/10760296241256368","DOIUrl":"10.1177/10760296241256368","url":null,"abstract":"<p><strong>Introduction: </strong>Venous thromboembolism (VTE) is a serious, frequent, and preventable medical complication in hospitalized patients. Although the efficacy of prophylaxis (pharmacological and/or mechanical) has been demonstrated, compliance with prophylaxis is poor at international and national levels.</p><p><strong>Aim: </strong>To determine the indication and use of pharmacological thromboprophylaxis in hospitalized patients in Uruguay.</p><p><strong>Methods: </strong>An observational, descriptive, cross-sectional, multicentre study involving 31 nationwide healthcare facilities was conducted. Baseline characteristics associated with hospital admission, the percentage of the population with an indication for thromboprophylaxis, and the percentage of patients receiving pharmacological thromboprophylaxis were assessed. The VTE risk was determined using the Padua score for medical patients; the Caprini score for surgical patients; the Royal College of Obstetricians and Gynaecologists (RCOG) guidelines for pregnant-postpartum patients.</p><p><strong>Results: </strong>1925 patients were included, representing 26% of hospitalized patients in Uruguay. 71.9% of all patients were at risk of VTE. Of all patients at risk of VTE, 58.6% received pharmacological thromboprophylaxis. The reasons for not receiving thromboprophylaxis were prescribing omissions in 16.1% of cases, contraindication in 15.9% and 9.4% of patients were already anticoagulated for other reasons. Overall, just 68% of patients were \"protected\" against VTE. Recommendations of major thromboprophylaxis guidelines were followed in 70.1% of patients at risk.</p><p><strong>Conclusions: </strong>Despite the progress made in adherence to thromboprophylaxis indications, nonadherence remains a problem, affecting one in six patients at risk of VTE in Uruguay.</p>","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"30 ","pages":"10760296241256368"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11135102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Bidirectional two-Sample Mendelian Randomization Study of the Association Between Venous Thromboembolism and Ischaemic Stroke.","authors":"Haibing Xiong, Xinhong Tian, Aiwei He, Tingting Chen, Yanlin Li, Jiajie Leng, Letai Li","doi":"10.1177/10760296241293333","DOIUrl":"10.1177/10760296241293333","url":null,"abstract":"<p><p>Previous clinical and epidemiological studies have shown that patients with venous thromboembolism (VTE) are comorbid with symptoms of ischaemic stroke (IS). Current understanding about increased risk of IS after VTE remain inconclusive. This study use a bidirectional two-sample Mendelian randomization (MR) study to explore the causality of VTE, pulmonary embolism (PE), deep vein thrombosis (DVT), and IS. This study used pooled data from published genome-wide association studies (GWAS). GWAS statisics of IS (from EBI database, n = 484 121), VTE (from Finngen database, n = 218 792), PE (from Finngen database, n = 218 413), and DVT (from UK biobank database, n = 337 159) were assessed. Forward and reverse MR analysis were conducted to explore the causal relationship between three type of the exposure (VTE, PE, and DVT) and the outcome (IS). Our primary causal inference method was Inverse Variance Weighted (IVW). Secondary inference methods were Weighted Median and MR-Egger. For the sensitive analysis, MR-PRESSO, MR-Egger intercept, Cochran's Q, leave-one method were used to consolidate our findings. In the foward MR analysis, VTE increased the risk of IS (OR_IVW= 1.034, <i>P</i>_IVW= 0.021) and PE was also a risk factor for IS (OR = 1.055, <i>P</i>_IVW= 0.009). There was no causality that DVT influenced on IS (<i>P</i>_IVW> 0.05). In the reverse MR analysis, IS came to be a risk factor for DVT (OR = 1.003, <i>P</i>_IVW= 0.046). Meanwhile, IS took not any causal effect on VTE and PE. All the results passed the reasonable sensitive analysis. Our findings provided genetic evidence that PE and VTE can lead to an increased risk of IS, whereas increased IS promoted the risk of DVT further. Our findings provided novel insights about the risk factors and management for IS.</p>","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"30 ","pages":"10760296241293333"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Knowledge, Adherence, and Satisfaction With Warfarin Therapy and Associated Factors Among Outpatients at University Teaching Hospital in Ethiopia\".","authors":"","doi":"10.1177/10760296241277140","DOIUrl":"10.1177/10760296241277140","url":null,"abstract":"","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"30 ","pages":"10760296241277140"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a Blood-Biomarker-Based Predictive Model for HBV-Associated Hepatocellular Carcinoma.","authors":"Yafeng Tan, Wei Xia, Fenglan Sun, Bing Mei, Yaoling Ouyang, Linyun Li, Zhenxia Chen, Song Wu, Jufang Tan, Zhaxi Pubu, Bu Sang, Tao Jiang","doi":"10.1177/10760296241298230","DOIUrl":"10.1177/10760296241298230","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to explore the optimal predictors of HBV-associated HCC using Lasso, and establish a prediction model.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on patients who underwent CBC and CRP testing between January 2016 and March 2024. The study population comprised 5441 cases divided into three cohorts: non-HBV-infected (1333 cases), HBV-infected (1023 cases), and HBV-associated HCC (3085 cases). A value of CRP <10 mg/L was used to exclude cases of acute bacterial infections. Baseline data and blood parameters were compared across the three groups (control group (n = 1049), the HBV-infected group (n = 789), and the HBV-associated HCC group (n = 1367)). HBV-infected group and the HBV-associated HCC group were used as modeling subjects which 70% were classified as training set (n = 1512) and 30% were classified as validation set (n = 644). Lasso regression and logistic regression were employed to identify the most effective predictors of HBV-associated HCC, which were subsequently incorporated into a predictive model by training set.</p><p><strong>Results: </strong>Significant variations in age, gender, and blood parameter indices were observed between individuals with acute bacterial infections and non-infections in the study population, and also between three groups. The optimal predictors identified for HBV-associated HCC included gender, age, MONO, EO%, MCHC, MPV, and PCT.</p><p><strong>Conclusions: </strong>The study highlights the significant impact of acute bacterial infections on immune status, erythrocyte system, and platelet system. After excluding acute bacterial infections, factors such as gender, age, MONO, EO%, MCHC, MPV, and PCT are effective predictors for clinical prediction of HCC development in HBV-infected patients.</p>","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"30 ","pages":"10760296241298230"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}